CA3076980A1 - Crystalline linagliptin intermediate and process for preparation of linagliptin - Google Patents

Crystalline linagliptin intermediate and process for preparation of linagliptin Download PDF

Info

Publication number
CA3076980A1
CA3076980A1 CA3076980A CA3076980A CA3076980A1 CA 3076980 A1 CA3076980 A1 CA 3076980A1 CA 3076980 A CA3076980 A CA 3076980A CA 3076980 A CA3076980 A CA 3076980A CA 3076980 A1 CA3076980 A1 CA 3076980A1
Authority
CA
Canada
Prior art keywords
formula
linagliptin
crystalline form
reaction mass
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3076980A
Other languages
English (en)
French (fr)
Inventor
Venkata Raghavendracharyulu Palle
Shanmughasamy Rajmahendra
Dharshan Jakkali CHANDREGOWDA
Thangarasu Ponnusamy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocon Ltd
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of CA3076980A1 publication Critical patent/CA3076980A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3076980A 2017-09-27 2018-09-27 Crystalline linagliptin intermediate and process for preparation of linagliptin Pending CA3076980A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201741034292 2017-09-27
IN201741034292 2017-09-27
PCT/IB2018/057484 WO2019064214A1 (en) 2017-09-27 2018-09-27 INTERMEDIATE OF CRYSTALLINE LINAGLIPTIN AND PROCESS FOR THE PREPARATION OF LINAGLIPTIN

Publications (1)

Publication Number Publication Date
CA3076980A1 true CA3076980A1 (en) 2019-04-04

Family

ID=65903063

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3076980A Pending CA3076980A1 (en) 2017-09-27 2018-09-27 Crystalline linagliptin intermediate and process for preparation of linagliptin

Country Status (10)

Country Link
US (1) US11040974B2 (https=)
JP (1) JP2020535193A (https=)
KR (1) KR20200092946A (https=)
CN (1) CN111511743A (https=)
AU (1) AU2018343236A1 (https=)
BR (1) BR112020005964A2 (https=)
CA (1) CA3076980A1 (https=)
MX (1) MX2020004050A (https=)
RU (1) RU2020114890A (https=)
WO (1) WO2019064214A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110684026A (zh) * 2019-10-24 2020-01-14 扬子江药业集团上海海尼药业有限公司 一种利格列汀的工业化制备方法
CN110872292B (zh) * 2019-11-30 2022-01-25 江苏君若药业有限公司 一条合成糖尿病药物利拉利汀的路线
EP4349837A1 (en) 2022-10-05 2024-04-10 Zaklady Farmaceutyczne "Polpharma" S.A. A pharmaceutical intermediate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
IN2013MU02055A (https=) * 2013-06-18 2015-07-03 Cadila Healthcare Ltd
WO2015011609A1 (en) * 2013-07-23 2015-01-29 Ranbaxy Laboratories Limited Process for the preparation of linagliptin and an intermediate thereof

Also Published As

Publication number Publication date
KR20200092946A (ko) 2020-08-04
AU2018343236A1 (en) 2020-05-14
JP2020535193A (ja) 2020-12-03
RU2020114890A (ru) 2021-10-27
CN111511743A (zh) 2020-08-07
WO2019064214A1 (en) 2019-04-04
US20200354363A1 (en) 2020-11-12
MX2020004050A (es) 2020-11-06
US11040974B2 (en) 2021-06-22
BR112020005964A2 (pt) 2020-10-06

Similar Documents

Publication Publication Date Title
TWI597280B (zh) 化合物之晶型、其製備及用途
KR20120083452A (ko) 피롤로［2,3-ｄ］피리미딘 화합물
EP3658552B1 (en) Process for preparing n-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamide by reacting the corresponding amine with a 3-halo-propionyl chloride
AU2021389180A9 (en) Heteroaryl carboxamide compound
US11040974B2 (en) Crystalline linagliptin intermediate and process for preparation of linagliptin
US20240217977A1 (en) Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof
US20250084086A1 (en) Process for preparing btk inhibitors
WO2016008461A1 (en) A new form of sofosbuvir and a method of its preparation
WO2021164793A1 (zh) 用作激酶抑制剂的化合物及其应用
CN102993205B (zh) 一种高收率制备高纯度西地那非游离碱的纯化方法
WO2025007801A1 (zh) 一种嘌呤类衍生物及其用途
WO2014129596A1 (ja) 三環性化合物の製造方法及び当該製造方法により得ることができる三環性化合物
CN111518045A (zh) 一种具有苯并七元环结构的化合物、其制备方法及用途
CN114685520A (zh) 三并环化合物及其药物组合物和应用
JP7607799B2 (ja) ６員芳香族ヘテロ尿素環の誘導体及びその使用
US20220009894A1 (en) 1,2,3,4-tetrahydroquinoxaline derivative, preparation method therefor and application thereof
CN110669027B (zh) 化合物和其酯、其制备方法和用途
KR20200092945A (ko) 레날리도마이드의 결정형
HK40021355B (en) Compound and ester thereof, method for producing and using same
HK40021355A (en) Compound and ester thereof, method for producing and using same
CN121399088A (zh) Kras g12d中间体的制备方法
CN120309585A (zh) 苯并嘧啶类化合物、其制备方法、药物组合物及应用
IL321757A (en) Naphthylamide compound, and preparation method therefor and use thereof
HK40096273A (zh) 用作d1正向别构调节剂的经取代的四氢异喹啉衍生物
HK1221214A1 (en) Method for preparing an atropisomer of a pyrrole derivative

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220930

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240724

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240827

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240827

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240827

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240919

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250215

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250215

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250819

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250819

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260414

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260414